1. Show article details.

    BeiGene to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

    Business Wire – 7:00 AM ET 11/23/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

  2. Show article details.

    BeiGene Announces the Approval of XGEVA® (Denosumab) in China for the Prevention of Skeletal-Related Events in Patients With Bone Metastases From Solid Tumors and in Patients With Multiple Myeloma

    Business Wire – 8:00 PM ET 11/19/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration has approved XGEVA® for the prevention of skeletal-related events in patients with bone metastases from solid tumors and in patients with multiple myeloma.

  3. Show article details.

    BeiGene Announces that RATIONALE 303 Trial of Tislelizumab in Non-Small Cell Lung Cancer Met the Primary Endpoint of Overall Survival at Interim Analysis

    Business Wire – 7:00 AM ET 11/17/2020

    RATIONALE 303 is a global Phase 3 trial of BeiGene’s anti-PD-1 antibody tislelizumab compared to docetaxel in the second- or third-line setting in patients with locally advanced or metastatic non-small cell lung cancer who progressed on prior platinum-based chemotherapy CAMBRIDGE, Mass.

  4. Show article details.

    EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China

    Business Wire – 7:04 AM ET 11/09/2020

    HEMEL HEMPSTEAD, England & BEIJING, China, & CAMBRIDGE, Mass. This press release features multimedia. “Dinutuximab beta represents an important biologic, which is already available to patients with high-risk neuroblastoma in Europe,” commented Xiaobin Wu, Ph.D., General Manager of China and President of BeiGene.

  5. Show article details.

    BeiGene Reports Third Quarter 2020 Financial Results

    Business Wire – 4:05 PM ET 11/05/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights, anticipated upcoming milestones, and financial results for the third quarter and first nine months of 2020.

  6. Show article details.

    BeiGene Announces Data on BRUKINSA® (Zanubrutinib) and Tislelizumab to Be Presented at the 62nd ASH Annual Meeting

    Business Wire – 9:00 AM ET 11/05/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical data on its BTK inhibitor BRUKINSA® and non-clinical data on its anti-PD-1 antibody tislelizumab will be presented in an oral presentation and four posters at the 62nd American Society for Hematology Annual Meeting, taking place virtual...

  7. Show article details.

    BioAtla and BeiGene Revise Global Development and Commercialization Agreement for Novel Conditionally Active Biologic CTLA-4 Candidate BA3071

    Business Wire – 7:00 AM ET 10/06/2020

    BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic protein therapeutics, and BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company, today announced that the two companies have revised their previous global co-development and commercialization agreement for BioAtla’s investigational CAB CTLA-4 antibody, BA3071.

  8. Show article details.

    Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

    PR Newswire – 7:00 AM ET 09/21/2020

    CAMBRIDGE, Mass. and BEIJING, Sept. 21, 2020  Leap Therapeutics (LPTX), Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the first patient has been dosed in the DisTinGuish study, a Phase 2a clinical tr...

  9. Show article details.

    BeiGene Presents Data at ESMO Virtual Congress 2020 on Phase 3 Trial of Tislelizumab in First-Line Non-Squamous Non-Small Cell Lung Cancer and Phase 2 Trial of Pamiparib in Advanced Ovarian Cancer

    Business Wire – 6:05 PM ET 09/17/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the first reported data from RATIONALE 304, the Phase 3 trial of its anti-PD-1 antibody tislelizumab in combination with chemotherapy as a potential first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung...

  10. Show article details.

    BeiGene to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

    Business Wire – 9:00 AM ET 09/10/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will present at the Morgan Stanley 18th Annual Global Healthcare Conference on Thursday, September 17, 2020 at 11:45 a.m. ET.

  11. Show article details.

    BeiGene Announces Acceptance and Priority Review by Health Canada of New Drug Submission for BRUKINSA® (zanubrutinib) in Waldenström’s Macroglobulinemia

    Business Wire – 7:00 AM ET 09/09/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its New Drug Submission for BRUKINSA® for the treatment of patients with Waldenström’s macroglobulinemia has been accepted by Health Canada and granted priority review status.

  12. Show article details.

    BeiGene Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs

    Business Wire – 9:15 AM ET 09/04/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the company’s ordinary shares, which trade on the Hong Kong Stock Exchange, will be included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective on September 7, 2020.

  13. Show article details.

    BeiGene Announces Exclusive License Agreement for Neutralizing COVID-19 Antibodies Developed by Singlomics Biopharmaceuticals

    Business Wire – 7:00 AM ET 08/27/2020

    Phase 1 and Phase 1/2 Clinical Trials Expected to Begin Enrolling Healthy Subjects and Patients with Mild to Moderate COVID-19 by early October BeiGene, Ltd. (BGNE) and Singlomics Biopharmaceuticals Co., Ltd., today announced that the companies have executed an exclusive license agreement for BeiGene (BGNE) to develop, manufacture and commercialize globally outside of greater China Singlomics’ investigationa...

  14. Show article details.

    BeiGene Reports Second Quarter 2020 Financial Results

    GlobeNewswire – 4:05 PM ET 08/06/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights, anticipated upcoming milestones, and financial results for the second quarter and first half of 2020.

  15. Show article details.

    BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress

    GlobeNewswire – 7:00 AM ET 08/05/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical and nonclinical data on its anti-PD-1 antibody tislelizumab and its investigational PARP inhibitor pamiparib will be presented in two mini oral presentations and five posters at the 2020 European Society for Medical Oncology Virtual Cong...

  16. Show article details.

    Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China

    GlobeNewswire – 9:15 AM ET 07/27/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company, today announced that the Center for Drug Evaluation of the China National Medical Products Administration has granted priority review status to the New Drug Application of pamiparib, BeiGene’s investigational inhibitor of PARP1 and PARP2, for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated advance...

  17. Show article details.

    Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection

    GlobeNewswire – 6:30 AM ET 07/20/2020

    -- BeiGene (BGNE) acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China ---- Assembly receives $40 million upfront payment and is eligible to receive up to $500 million in potential development, regulatory, and sales milestone payments plus royalties on product sales ---- Assembly to host webcast and conference call today at 8:30 am ET -- SOUTH SAN...

  18. Show article details.

    BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China

    GlobeNewswire – 9:00 AM ET 07/17/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Center for Drug Evaluation of the China National Medical Products Administration has accepted a new drug application of BeiGene’s investigational inhibitor of PARP1 and PARP2, pamiparib, ...

  19. Show article details.

    BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering

    GlobeNewswire – 5:00 PM ET 07/15/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the closing of a registered direct offering of 145,838,979 ordinary shares, par value $0.0001 per share, to certain existing investors.

  20. Show article details.

    BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering

    GlobeNewswire – 8:00 PM ET 07/12/2020

    BeiGene, Ltd. (BGNE), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the pricing of a registered direct offering of 145,838,979 ordinary shares, par value $0.0001 per share, to certain existing investors.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Aug
    06

    BGNE announced Q2 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.